Want to see TPST full AI Analyst Report?
TPST Stock Chart & Stats
$1.96
$0.02(2.27%)
At close: 4:00 PM EST
$1.96
$0.02(2.27%)
Day’s Range― - ―
52-Week Range$1.02 - $12.23
Previous CloseN/A
Volume2.28M
Average Volume (3M)50.79K
Market Cap
$17.42M
Enterprise Value$11.60M
Total Cash (Recent Filing)$1.80M
Total Debt (Recent Filing)$7.85M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Aug 17, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.21
Shares Outstanding15,979,411
10 Day Avg. Volume57,939
30 Day Avg. Volume50,791
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.44
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.52
Enterprise Value/Ebitda-0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition And LeadershipAcquisition added a clinically de‑risked cell therapy and installed experienced leadership as CEO, strengthening operational capability to advance the lead program.
Clinical EfficacyLead dual-target CAR-T produced complete remissions and durable disease control in early patients while showing a favorable safety profile, supporting commercial potential in hard-to-treat cancers.
Regulatory PathwayPlanned registrational clinical trial for the lead CAR-T establishes a clear pathway toward potential regulatory approval and future commercialization.
Bears Say
Deprioritization Of Legacy AssetsLegacy oncology programs such as amezalpat and TPST‑1495 are being deprioritized and may stall without new financing or partnership support, reducing near-term asset value.
Development Funding GapAdvancement of legacy drug programs will require additional financing or partnerships, creating execution risk if new funding is not secured.
Shareholder DilutionTransaction structure causes existing shareholders to lose majority ownership and face substantial dilution, which can put downward pressure on the stock.
Tempest Therapeutics News
TPST FAQ
What was Tempest Therapeutics’s price range in the past 12 months?
Tempest Therapeutics lowest stock price was $1.02 and its highest was $12.23 in the past 12 months.
What is Tempest Therapeutics’s market cap?
Tempest Therapeutics’s market cap is $17.42M.
When is Tempest Therapeutics’s upcoming earnings report date?
Tempest Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 45 days.
How were Tempest Therapeutics’s earnings last quarter?
Tempest Therapeutics released its earnings results on May 14, 2026. The company reported -$2.53 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$2.25.
Is Tempest Therapeutics overvalued?
According to Wall Street analysts Tempest Therapeutics’s price is currently Overvalued.
Does Tempest Therapeutics pay dividends?
Tempest Therapeutics does not currently pay dividends.
What is Tempest Therapeutics’s EPS estimate?
Tempest Therapeutics’s EPS estimate is -0.3.
How many shares outstanding does Tempest Therapeutics have?
Tempest Therapeutics has 15,979,411 shares outstanding.
What happened to Tempest Therapeutics’s price movement after its last earnings report?
Tempest Therapeutics reported an EPS of -$2.53 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went down -12.44%.
Which hedge fund is a major shareholder of Tempest Therapeutics?
Currently, no hedge funds are holding shares in TPST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tempest Therapeutics
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Technical Analysis
Ownership Overview
1.45% Insiders
1.69% Mutual Funds
0.11% Other Institutional Investors
95.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---